# Amgen Inc. (AMGN) FY2025 Q3 P&L / Income Statement

- Company: Amgen Inc. (AMGN)
- Period: 2025-07-01 to 2025-09-30
- Filing: Q3 FY2025 10-Q, filed 2025-11-05, accession number 0000318154-25-000072
- Page: https://plicit.ai/financials/amgn/fy2025-q3-income-statement
- Chart image: https://plicit.ai/charts/amgn-fy2025-q3-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2025-07-01 through 2025-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 9,557,000,000 US dollars
- **Cost of sales**: 3,082,000,000 US dollars
- **Gross profit (calculated)**: 6,475,000,000 US dollars
- **Operating expenses (calculated)**: 3,949,000,000 US dollars
- **Operating income**: 2,526,000,000 US dollars
- **Other income (expense), net (calculated)**: 1,395,000,000 US dollars
- **Income before income taxes**: 3,921,000,000 US dollars
- **Provision for income taxes**: 705,000,000 US dollars
- **Net income**: 3,216,000,000 US dollars
- **Aranesp - UNITED STATES**: 103,000,000 US dollars
- **Aranesp - Non-US**: 254,000,000 US dollars
- **BLINCYTO - UNITED STATES**: 236,000,000 US dollars
- **BLINCYTO - Non-US**: 156,000,000 US dollars
- **EVENITY - UNITED STATES**: 417,000,000 US dollars
- **EVENITY - Non-US**: 124,000,000 US dollars
- **ENBREL - UNITED STATES**: 574,000,000 US dollars
- **ENBREL - Non-US**: 6,000,000 US dollars
- **KRYSTEXXA - UNITED STATES**: 320,000,000 US dollars
- **KRYSTEXXA - Non-US**: 0 US dollars
- **Kyprolis - UNITED STATES**: 225,000,000 US dollars
- **Kyprolis - Non-US**: 134,000,000 US dollars
- **Nplate - UNITED STATES**: 333,000,000 US dollars
- **Nplate - Non-US**: 124,000,000 US dollars
- **Otezla - UNITED STATES**: 473,000,000 US dollars
- **Otezla - Non-US**: 112,000,000 US dollars
- **Other products - UNITED STATES**: 1,408,000,000 US dollars
- **Other products - Non-US**: 445,000,000 US dollars
- **Prolia - UNITED STATES**: 806,000,000 US dollars
- **Prolia - Non-US**: 333,000,000 US dollars
- **Repatha - UNITED STATES**: 442,000,000 US dollars
- **Repatha - Non-US**: 352,000,000 US dollars
- **TEPEZZA - UNITED STATES**: 518,000,000 US dollars
- **TEPEZZA - Non-US**: 42,000,000 US dollars
- **TEZSPIRE - UNITED STATES**: 377,000,000 US dollars
- **TEZSPIRE - Non-US**: 0 US dollars
- **Vectibix - UNITED STATES**: 162,000,000 US dollars
- **Vectibix - Non-US**: 122,000,000 US dollars
- **XGEVA - UNITED STATES**: 357,000,000 US dollars
- **XGEVA - Non-US**: 182,000,000 US dollars
- **Product sales - UNITED STATES**: 6,751,000,000 US dollars
- **Product sales - Non-US**: 2,386,000,000 US dollars
- **Selling, general and administrative**: 1,720,000,000 US dollars
- **Research and development**: 1,900,000,000 US dollars
- **Other**: 329,000,000 US dollars
- **Revenue before reconciliation (calculated)**: 18,274,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Components above reported revenue (calculated)**: negative 8,717,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.

## Chart details: Revenue by Product and Service (16 categories)

- Page: https://plicit.ai/financials/amgn/fy2025-q3-income-statement/revenue-by-product-and-service-16-categories
- Chart image: https://plicit.ai/charts/amgn-fy2025-q3-revenue-by-product-and-service-16-categories-sankey.png

Income statement for 2025-07-01 through 2025-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 9,557,000,000 US dollars
- **Cost of sales**: 3,082,000,000 US dollars
- **Gross profit (calculated)**: 6,475,000,000 US dollars
- **Operating expenses (calculated)**: 3,949,000,000 US dollars
- **Operating income**: 2,526,000,000 US dollars
- **Other income (expense), net (calculated)**: 1,395,000,000 US dollars
- **Income before income taxes**: 3,921,000,000 US dollars
- **Provision for income taxes**: 705,000,000 US dollars
- **Net income**: 3,216,000,000 US dollars
- **Prolia**: 1,139,000,000 US dollars
- **Repatha**: 794,000,000 US dollars
- **ENBREL**: 580,000,000 US dollars
- **Otezla**: 585,000,000 US dollars
- **XGEVA**: 539,000,000 US dollars
- **EVENITY**: 541,000,000 US dollars
- **TEPEZZA**: 560,000,000 US dollars
- **BLINCYTO**: 392,000,000 US dollars
- **Nplate**: 457,000,000 US dollars
- **Kyprolis**: 359,000,000 US dollars
- **Aranesp**: 357,000,000 US dollars
- **TEZSPIRE**: 377,000,000 US dollars
- **KRYSTEXXA**: 320,000,000 US dollars
- **Vectibix**: 284,000,000 US dollars
- **Other products**: 1,853,000,000 US dollars
- **Other revenues**: 420,000,000 US dollars
- **Selling, general and administrative**: 1,720,000,000 US dollars
- **Research and development**: 1,900,000,000 US dollars
- **Other**: 329,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2 categories)

- Page: https://plicit.ai/financials/amgn/fy2025-q3-income-statement/revenue-by-product-and-service-2-categories
- Chart image: https://plicit.ai/charts/amgn-fy2025-q3-revenue-by-product-and-service-2-categories-sankey.png

Income statement for 2025-07-01 through 2025-09-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 9,557,000,000 US dollars
- **Cost of sales**: 3,082,000,000 US dollars
- **Gross profit (calculated)**: 6,475,000,000 US dollars
- **Operating expenses (calculated)**: 3,949,000,000 US dollars
- **Operating income**: 2,526,000,000 US dollars
- **Other income (expense), net (calculated)**: 1,395,000,000 US dollars
- **Income before income taxes**: 3,921,000,000 US dollars
- **Provision for income taxes**: 705,000,000 US dollars
- **Net income**: 3,216,000,000 US dollars
- **Product sales**: 9,137,000,000 US dollars
- **Other revenues**: 420,000,000 US dollars
- **Selling, general and administrative**: 1,720,000,000 US dollars
- **Research and development**: 1,900,000,000 US dollars
- **Other**: 329,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.